文献速递类风湿关节炎脊柱关节炎其他结缔组织病

塞妥珠单抗聚乙二醇在多种适应症中的长期安全性:11,317例临床试验患者的汇总分析

Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials.
PubMed 文献 · RMD Open · 2019-05-31

结果显示感染是最常见的严重不良事件,总体发生率3.62/100患者年,不同适应症间有差异;恶性肿瘤、主要心血管不良事件和胃肠道穿孔发生率较低,死亡和恶性肿瘤发生率与一般人群预期一致,未发现新的安全性信号。

要点

  • 感染是最常见的严重不良事件,总体发生率3.62/100患者年,克罗恩病最高(5.97/100患者年)。
  • 恶性肿瘤发生率0.82/100患者年,主要心血管不良事件0.47/100患者年,胃肠道穿孔0.08/100患者年。
  • 死亡和恶性肿瘤发生率与一般人群预期数据一致,未发现新的安全性信号。

核心结论

  • 在大规模临床试验汇总分析中,塞妥珠单抗聚乙二醇未发现新的安全性信号,死亡和恶性肿瘤发生率与一般人群预期一致。

研究设计与样本

  • 汇总49项UCB申办的塞妥珠单抗聚乙二醇临床试验(27项类风湿关节炎、1项中轴型脊柱关节炎、1项银屑病关节炎、5项银屑病、15项克罗恩病)至2017年8月的数据。
  • 严重不良事件和死亡由外部专家委员会依据预设病例规则进行医学审阅。

主要发现

  • 感染是最常见的严重不良事件,总体发生率为3.62/100患者年,范围从银屑病的1.50/100患者年至克罗恩病的5.97/100患者年。
  • 恶性肿瘤发生率为0.82/100患者年,其中淋巴瘤为0.06/100患者年。
  • 主要心血管不良事件发生率为0.47/100患者年,胃肠道穿孔发生率为0.08/100患者年,分别在类风湿关节炎和克罗恩病患者中最高。
  • 银屑病患者的严重不良事件发生率最低。
  • 死亡和恶性肿瘤发生率与一般人群预期数据一致。

关键数值与推荐

  • 感染总体发生率3.62/100患者年(范围1.50-5.97/100患者年)。
  • 恶性肿瘤发生率0.82/100患者年,淋巴瘤0.06/100患者年。
  • 主要心血管不良事件发生率0.47/100患者年,胃肠道穿孔0.08/100患者年。
  • 标准ised死亡率和恶性肿瘤率使用WHO/GLOBOCAN/SEER数据库计算。

临床怎么用

  • 长期使用塞妥珠单抗聚乙二醇时,应关注感染风险,尤其克罗恩病患者感染发生率较高。
  • 不同适应症间严重不良事件发生率存在差异,可能反映基础炎症疾病的不同。
  • 未发现新的安全性信号,支持该药在获批适应症中的长期安全性。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To review long-term certolizumab pegol (CZP) safety across all approved indications: rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), psoriasis (PSO) and Crohn's disease (CD). METHODS: Data were pooled across 49 UCB-sponsored CZP clinical trials (27 RA, one axSpA, one PsA, five PSO, 15 CD) to August 2017. Serious adverse events (SAEs) of interest (infections, malignancies, autoimmunity/hypersensitivity events, major adverse cardiovascular events (MACE), gastrointestinal (GI) perforations, psoriasis events, laboratory abnormalities) and deaths were medically reviewed by an external expert committee, using predefined case rules. Incidence rates (IRs)/100 patient-years (PY) are presented by indication; standardised mortality and malignancy rates were calculated using WHO/GLOBOCAN/SEER databases. Pregnancies with maternal CZP exposure are also reported. RESULTS: Of 11 317 CZP-treated patients across indications (21 695 PY CZP exposure; maximum: 7.8 years), infections were the most common SAEs (overall IR: 3.62/100 PY; IRs ranged from 1.50/100 PY(PSO) to 5.97/100 PY(CD)). The IR for malignancies was 0.82/100 PY, including lymphoma (0.06/100 PY). MACE and GI perforation IRs in CZP-treated patients were 0.47/100 PY and 0.08/100 PY and were highest in RA and CD, respectively. Patients with PSO had the lowest SAE rates. The incidence of deaths and malignancies aligned with expected general population data. CONCLUSION: This extensive overview of the CZP safety profile in clinical trials, across all indications, provides large-scale confirmation of previous reports. No new safety signals or relevant non-disease-related laboratory abnormalities were identified. The study demonstrated some indication-specific differences in certain SAE rates that may be attributable to the underlying inflammatory disease.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Curtis JR, Mariette X, Gaujoux-Viala C, et al. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials. RMD Open. 2019. PMID: 31245056. doi:10.1136/rmdopen-2019-000942

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。